ONCOLOGY Vol 38, Issue 8

Quadruplet therapy is making a run to be a potential standard of care in frontline multiple myeloma, according to a panel of experts.

The approval of epcoritamab may impact treatment options in the R/R follicular lymphoma space, according to Tycel Phillips, MD.

Neil M. Iyengar, MD, highlights how to best integrate exercise oncology into multidisciplinary care.

Krystal Preston, PharmD, BCPS, discussed the use and administration of tislelizumab for patients with resectable or metastatic esophageal squamous cell carcinoma.

Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.